Links to Data sources

Sr. No Display Name Type Country Last Updated
1 GePaRD Data Source Germany 13/11/2018

Links to Studies

Status Official Title Lead Investigator Last Updated
Finalised Dulaglutide Modified-Prescription-Event Monitoring Study and network database study: a multi-database collaborative research program of observational studies to monitor the utilisation and safety of dulaglutide in the EU Professor Saad Shakir 11/11/2021
Finalised A pharmacoepidemiological study of Rivaroxaban use and potential adverse outcomes in routine clinical pratice in Germany Dr Tania Schink 30/09/2021
Finalised Intravenous Iron Postauthorisation Safety Study (PASS): Evaluation of the Risk of Severe Hypersensitivity Reactions Mrs Lia Gutierrez 08/09/2021
Finalised Cohort Study of the Relative Incidence of Major Cardiovascular Events Among Patients Initiating Prucalopride Versus a Matched Comparator Cohort Dr Alicia Gilsenan 06/09/2021
Finalised Background rates of Adverse Events of Special Interest for monitoring COVID-19 vaccines Professor Miriam Sturkenboom 26/08/2021
Finalised Post-Authorisation Safety Study of Agomelatine and the Risk of Hospitalisation for Acute Liver Injury Dr Manel Pladevall 28/01/2021
Finalised Aclidinium Bromide Drug Utilisation Post-Authorisation Safety Studies (DUS): Common Protocol for Aclidinium (DUS1) and Aclidinium/Formoterol Fixed-Dose Combination (DUS2) Dr Cristina Rebordosa 26/01/2021
Finalised Adherence, persistence and switching patterns – once- and twice-daily direct oral anticoagulants Dr Ron Herings 19/12/2019
Finalised The risk of ischemic cardiovascular events associated with oxycodone/naloxone use Dr Tania Schink 21/03/2019
Finalised Estimation of Background Incidence Rates of Guillain-Barré Syndrome in Germany in the years 2007-2009 Dr Tania Schink 21/03/2019
Finalised Risk of Febrile Convulsions after a Second Immunization against Measles, Mumps and Rubella with MMRV as compared to MMR or MMR+V. Dr Tania Schink 21/03/2019
Finalised Thromboembolic Risk in Patients with Chronic Kidney Disease Treated receiving Epoetin zeta or other Erythropoietin Stimulating Agents – the BIPS study Dr Tania Schink 21/03/2019
Finalised Risk of Venous Thromboembolism and All-Cause Mortality in Cancer Patients Treated with Epoetins either with or without Transfusions versus Cancer Patients Treated with Transfusions alone. Dr Tania Schink 21/03/2019
Finalised Pharmacoepidemiological Safety Study of Neuroleptics and Antidepressants in the Area of Geriatric Psychiatrics. Dr Tania Schink 21/03/2019
Finalised Risk of Febrile Convulsions after 1st dose MMRV vaccination in comparison to MMR and MMR+V vaccination. Dr Tania Schink 21/03/2019
Finalised Second primary cancers in patients with castration resistant prostate cancer (BOCARP) Dr Riedel Oliver 21/11/2018
Finalised Cilostazol Drug Utilisation Study Dr Jordi Castellsague 25/07/2018
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Comparative studies Professor Miriam Sturkenboom 25/08/2017
Finalised Safety Evaluation of Adverse Reactions in Diabetes - Drug utilisation studies Professor Miriam Sturkenboom 25/08/2017
Finalised Database study of lenalidomide (Revlimid®) in Germany: Monitoring off-label use Dr Oliver Riedel 02/08/2017
Finalised Off-label use of neuroleptics and antidepressants and risks of psychostimulant use in ADHD patients during childhood and adolescents Dr Oliver Riedel 31/01/2017
Finalised Burden of Herpes Zoster in selected immunocompromised populations in the German Pharmacoepidemiological Research Database (GePaRD) Dr Oliver Riedel 25/01/2017
Finalised Database Study of Thalidomide (Thalidomide Celgene®) in Germany: Monitoring Off-Label Use Dr Oliver Riedel 16/12/2016
Ongoing Exposure to SSRI/SNRI and depression in pregnancy and long-term childhood outcomes: the effect of modifying factors Dr Maria Loane 04/10/2021
Ongoing Studying drug exposure when disease is measured through accurate identification of an incident case: application to breast cancer in pregnancy Dr Maarit Leinonen 04/10/2021
Ongoing Long-Term Post-Marketing Observational Study of the Safety of Roflumilast Professor Edeltraud Garbe 28/04/2021
Ongoing ACCESS template protocol for safety of COVID-19 vaccines Professor Miriam Sturkenboom 19/02/2021
Ongoing VALIDATION STUDY PROTOCOL (OP0007) FOR THE EUROPEAN NON-INTERVENTIONAL POST- AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS CARDIOVASCULAR EVENTS OF MYOCARDIAL INFARCTION AND STROKE AND ALL-CAUSE MORTALITY FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0004) AND EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE (OP0006) Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST AUTHORIZATION SAFETY STUDY RELATED TO SERIOUS INFECTIONS FOR ROMOSOZUMAB BY THE EU ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing EUROPEAN NON-INTERVENTIONAL POST-AUTHORIZATION SAFETY STUDY RELATED TO ADHERENCE TO THE RISK MINIMIZATION MEASURES FOR ROMOSOZUMAB BY THE EU-ADR ALLIANCE Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing European non-interventional post-authorization safety study related to serious cardiovascular events of myocardial infarction and stroke, and all-cause mortality for romosozumab by the EU-ADR Alliance Dr Clinical Trial Registries and Results Personal data of lead investigator will not be disclosed because his/her consent required for disclosure according to applicable data protection laws is not available. 29/10/2020
Ongoing Extrapyramidal symptoms in patients treated with Abilify Maintena®: Cohort study with a 2-year follow-up using European automated healthcare databases Dr Non-interventional Research Manager H. Lundbeck A/S 01/09/2020
Ongoing A Retrospective Cohort Study to Assess Drug Utilisation and Long-Term Safety of Galcanezumab in European Patients in the Course of Routine Clinical Care Dr Krista Schroeder 30/07/2020
Planned The BRodalumab Assessment of Hazards: A Multinational Safety (BRAHMS) study in electronic healthcare databases Professor Jesper Hallas 05/10/2021
Planned Demonstrating solutions for studying intermittent medication exposures in diseases with episodic manifestations during pregnancy: application to medication for migraine in pregnancy Professor Hedvig Nordeng 04/10/2021
Planned A non-interventional post-authorisation safety study to investigate the risk of mortality in multiple sclerosis patients treated with alemtuzumab (LEMTRADA®) relative to comparable multiple sclerosis patients using other disease modifying therapies: a cohort study Professor Philippe Autier 26/08/2021
Planned Description of international collaboration in the area of medicines use and effects in COVID-19 affected pregnancies (CONSIGN-International)) Professor Miriam Sturkenboom 26/08/2021
Planned Drug utilisation study of Radium 223 under routine clinical practice in Europe Dr Bayer Clinical Trials BAYER AG 16/08/2021
Planned CONSIGN study: COVID-19 infection and medicines in pregnancy - a multinational registry based study Professor Hedvig Nordeng 10/02/2021